GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
NCT05532020 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect76/100
StatusWITHDRAWN
PhasePHASE2
Lead sponsorSoleno Therapeutics, Inc.
Last update2026-10-13
Public-record facts
| Intervention | DCCR (diazoxide choline) extended-release tablets (DRUG) |
|---|---|
| Condition | SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant), SIM1 Deficiency Obesity |
| Enrollment | 0 |
| Why stopped | Company Decision |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is withdrawn and was updated 2026-10-13.
- It is an interventional PHASE2 study with a named drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT05532020. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.